259 related articles for article (PubMed ID: 1909562)
1. rIL-4 differentially regulates rIL-2-induced murine NK and LAK killing in CD8+ and CD8- precursor cell subsets.
Merrow MW; Huber BT
Int Immunol; 1991 Jun; 3(6):551-61. PubMed ID: 1909562
[TBL] [Abstract][Full Text] [Related]
2. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
Mulé JJ; Krosnick JA; Rosenberg SA
J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
[TBL] [Abstract][Full Text] [Related]
3. Induction of murine lymphokine-activated killer cells by recombinant IL-7.
Lynch DH; Miller RE
J Immunol; 1990 Sep; 145(6):1983-90. PubMed ID: 1975262
[TBL] [Abstract][Full Text] [Related]
4. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
[TBL] [Abstract][Full Text] [Related]
5. Lymphokine-activated killer (LAK) cells. IV. Characterization of murine LAK effector subpopulations.
Ballas ZK; Rasmussen W
J Immunol; 1990 Jan; 144(1):386-95. PubMed ID: 2104892
[TBL] [Abstract][Full Text] [Related]
6. Lymphokine-activated killer cells. VII. IL-4 induces an NK1.1+CD8 alpha+beta- TCR-alpha beta B220+ lymphokine-activated killer subset.
Ballas ZK; Rasmussen W
J Immunol; 1993 Jan; 150(1):17-30. PubMed ID: 7678028
[TBL] [Abstract][Full Text] [Related]
7. Phenotypic and functional heterogeneity of thymic and splenic lymphokine activated killer cells relative to ornithine sensitivity.
Mehrotra P; Bear HD; Susskind BM
Cell Immunol; 1991 Feb; 132(2):451-65. PubMed ID: 1899052
[TBL] [Abstract][Full Text] [Related]
8. Interleukin 7 enhances cytolytic T lymphocyte generation and induces lymphokine-activated killer cells from human peripheral blood.
Alderson MR; Sassenfeld HM; Widmer MB
J Exp Med; 1990 Aug; 172(2):577-87. PubMed ID: 2142722
[TBL] [Abstract][Full Text] [Related]
9. A functional and phenotypic comparison of murine natural killer (NK) cells and lymphokine-activated killer (LAK) cells.
Hoskin DW; Stankova J; Anderson SK; Roder JC
Int J Cancer; 1989 May; 43(5):940-8. PubMed ID: 2469657
[TBL] [Abstract][Full Text] [Related]
10. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
Colquhoun SD; Economou JS; Shau H; Golub SH
J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
Kalland T; Belfrage H; Bhiladvala P; Hedlund G
J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
[TBL] [Abstract][Full Text] [Related]
12. Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2.
McKenzie RS; Simms PE; Helfrich BA; Fisher RI; Ellis TM
Cancer Res; 1992 Nov; 52(22):6318-22. PubMed ID: 1384959
[TBL] [Abstract][Full Text] [Related]
13. IL-4-induced lymphokine-activated killer cells. Lytic activity is mediated by phenotypically distinct natural killer-like and T cell-like large granular lymphocytes.
Peace DJ; Kern DE; Schultz KR; Greenberg PD; Cheever MA
J Immunol; 1988 May; 140(10):3679-85. PubMed ID: 2896213
[TBL] [Abstract][Full Text] [Related]
14. Effects of transforming growth factor-beta on human lymphokine-activated killer cell precursors. Autocrine inhibition of cellular proliferation and differentiation to immune killer cells.
Kasid A; Bell GI; Director EP
J Immunol; 1988 Jul; 141(2):690-8. PubMed ID: 3133414
[TBL] [Abstract][Full Text] [Related]
15. Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells.
Tilden AB; Itoh K; Balch CM
J Immunol; 1987 Feb; 138(4):1068-73. PubMed ID: 3100627
[TBL] [Abstract][Full Text] [Related]
16. Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells.
Grimm EA; Ramsey KM; Mazumder A; Wilson DJ; Djeu JY; Rosenberg SA
J Exp Med; 1983 Mar; 157(3):884-97. PubMed ID: 6601174
[TBL] [Abstract][Full Text] [Related]
17. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells.
Vujanovic NL; Herberman RB; Olszowy MW; Cramer DV; Salup RR; Reynolds CW; Hiserodt JC
Cancer Res; 1988 Feb; 48(4):884-90. PubMed ID: 3257412
[TBL] [Abstract][Full Text] [Related]
18. Lymphokine-activated killer (LAK) cells. VI. NK1.1+, CD3+ LAK effectors are derived from CD4-, CD8-, NK1.1- precursors.
Ballas ZK; Rasmussen W
Cell Immunol; 1991 May; 134(2):296-313. PubMed ID: 1827045
[TBL] [Abstract][Full Text] [Related]
19. Differential sensitivity of cytotoxic T lymphocytes and lymphokine-activated killer cells to inhibition by L-ornithine.
Susskind BM; Sekar J; Tandon PM; Lind DS; Bear HD
Cell Immunol; 1991 Mar; 133(1):41-54. PubMed ID: 1899361
[TBL] [Abstract][Full Text] [Related]
20. Precursor phenotype of lymphokine-activated killer cells in the mouse.
Salup RR; Mathieson BJ; Wiltrout RH
J Immunol; 1987 Jun; 138(11):3635-9. PubMed ID: 3108370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
